Liver cancer incidence tied to fatty liver disease is soaring, demanding innovative treatments for improved survival rates. Recent research uncovered a groundbreaking strategy that disrupts fat metabolism to transform immune-cold tumors into immune-hot battlegrounds. By inhibiting ATP citrate lyase (ACLY), a crucial enzyme converting glucose into fat, researchers altered the tumor microenvironment, unleashing a robust immune response led surprisingly by B cells rather than conventional T cells.
In a Nature study titled “ACLY inhibition promotes tumor immunity and suppresses liver cancer,” the team demonstrated that targeting tumor metabolism via ACLY inhibition reprograms the microenvironment, enhancing immune surveillance. This novel approach not only curbed tumor growth and fat accumulation but also stimulated immune infiltration, particularly of B cells crucial for effective tumor elimination. The unique metabolic rewiring in metabolic dysfunction–associated steatohepatitis-driven hepatocellular carcinoma (MASH-HCC) creates an immunosuppressive setting, presenting an opportunity for intervention through ACLY suppression.
Central to this research is EVT0185, a novel small molecule selectively activated in liver and tumor cells, sparing immune cells and showcasing efficacy across various MASH-HCC mouse models. Unexpectedly, ACLY inhibition led to a surge in tumor-infiltrating B cells and tertiary lymphoid structure formation, with B cells playing a pivotal role in the therapeutic benefits. Furthermore, EVT0185 increased CXCL13 levels, promoting B cell attraction and TLS formation associated with improved hepatocellular carcinoma outcomes.
This study sheds light on the critical role of tumor metabolism in immune evasion and introduces a novel immunometabolic therapeutic approach that shifts the metabolic programming of tumors to enhance immune visibility. By diverging from traditional methods targeting surface receptors or immune checkpoints, this strategy proves especially promising in addressing the limited efficacy of standard immunotherapies in MASH-HCC, opening new avenues for personalized and effective cancer treatments.
The research team’s transition to clinical trials with EVT0185 marks a significant step towards translating these findings into potential clinical applications. By reshaping how immune reprogramming is perceived in cancer, particularly by highlighting the substantial impact of B cells, this study paves the way for a new era of immunometabolic therapies targeting metabolic vulnerabilities in tumors. Through this innovative approach, researchers aim to redefine cancer treatment paradigms, emphasizing the potential of metabolic rewiring as a powerful immunotherapeutic tool.
Key Takeaways:
– Inhibiting ACLY in liver tumors reprograms the microenvironment, boosting immune surveillance led by B cells.
– EVT0185, a liver and tumor cell-selective small molecule, shows promising therapeutic effects in MASH-HCC mouse models.
– By enhancing B cell infiltration and promoting TLS formation, ACLY inhibition offers new insights into immune reprogramming in cancer.
– This immunometabolic strategy signifies a paradigm shift in cancer treatment, emphasizing metabolic rewiring as a potent immunotherapeutic lever.
Read more on genengnews.com